NCR Online Journal

Pancreatic Cancer Market is expected to grow at a CAGR of 7.3 % by 2032, estimates DelveInsight | Companies – AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb

 Breaking News
  • No posts were found

Pancreatic Cancer Market is expected to grow at a CAGR of 7.3 % by 2032, estimates DelveInsight | Companies – AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb

March 22
04:33 2023
Pancreatic Cancer Market is expected to grow at a CAGR of 7.3 % by 2032, estimates DelveInsight | Companies - AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb
Pancreatic Cancer Market

DelveInsight’s “Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. 

The Pancreatic Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Pancreatic Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Pancreatic Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Pancreatic Cancer market.

 

Request for a Free Sample Report @ Pancreatic Cancer Market Insight

 

Some facts of Pancreatic Cancer Market are:

  • According to DelveInsight, the pancreatic cancer market size in the 7MM was approximately USD 1,649 million in 2021.
  • According to DelveInsight, the total incident cases of pancreatic cancer were approx 175K in the 7MM in 2021. 
  • Major pancreatic cancer companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others are developing novel pancreatic cancer drugs that can be available in the pancreatic cancer market in the upcoming years.
  • The pancreatic cancer therapies in the pipeline include Motixafortide, Mitazalimab,  BPX-601, Tedopi (OSE2101), AZD5305,  Elraglusib (9 ING 41),  NT-I7 (Efineptakin Alfa),  Olaptesed pegol (NOX-A12),  siG12D LODER, Sotorasib (LUMAKRAS/AMG 510),  NGM120, Zenocutuzumab (Zeno, MCLA-128),  Adagrasib (MRTX849), RX-3117, Anktiva (N-803), BPM31510 (ubidecarenone), Zejula (niraparib), Glufosfamide, LOAd703 (delolimogene mupadenorepvec), Pamrevlumab, GVAX Pancreatic Tumor Vaccine, and others.
  • The pancreatic cancer market is expected to grow due to factors like an increase in the patient pool and the expected launch of novel emerging therapies.

 

Pancreatic Cancer Overview

Pancreatic cancer develops in the tissues of the pancreas, an organ in the abdomen located behind the bottom portion of the stomach. The pancreas produces hormones that assist control blood sugar and release enzymes that promote digestion. Pancreatic cancer is a disorder in which malignant (cancer) cells originate in pancreatic tissues. The pancreas can grow in various ways, including malignant and noncancerous tumors. However, the exact pancreatic cancer causes are unknown. The average life expectancy of pancreatic cancer for individuals who are diagnosed before the tumor develops or spreads is 3 to 3.5 years.

 

Learn more about Pancreatic Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market

 

Pancreatic Cancer Market 

The Pancreatic Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Pancreatic Cancer market trends by analyzing the impact of current Pancreatic Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Pancreatic Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pancreatic Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pancreatic Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Pancreatic Cancer Epidemiology 

The Pancreatic Cancer epidemiology section provides insights into the historical and current Pancreatic Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pancreatic Cancer market report also provides the diagnosed patient pool, trends, and assumptions. 

 

Explore more about Pancreatic Cancer Epidemiology @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market

 

Pancreatic Cancer Pipeline Therapies and Key Companies

  • Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme
  • Mitazalimab (ADC-1013): Alligator Bioscience
  • BPX-601: Bellicum Pharmaceuticals
  • Tedopi (OSE2101): OSE Immunotherapeutics
  • AZD5305: Astra Zeneca
  • Elraglusib (9 ING 41): Actuate Therapeutics
  • Pamrevlumab (FG-3019): FibroGen
  • NT-I7 (Efineptakin Alfa): NeoImmuneTech
  • Olaptesed pegol (NOX-A12): NOXXON Pharma
  • siG12D LODER: Silenseed Ltd
  • Sotorasib (LUMAKRAS/AMG 510): Amgen
  • NGM120: NGM Biopharmaceuticals
  • Zenocutuzumab (Zeno, MCLA-128): Merus
  • Adagrasib (MRTX849): Mirati Therapeutics
  • RX-3117: Rexahn Pharmaceuticals/Ocuphire Pharma/Processa Pharmaceuticals
  • Anktiva (N-803): ImmunityBio
  • BPM31510 (ubidecarenone): Berg
  • SBP-101: Panbela Therapeutics
  • Zejula (niraparib): GlaxoSmithKline/Bristol Myers Squibb
  • Glufosfamide: Eleison Pharmaceuticals/Molecular Templates
  • LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
  • CAN04 (Nadunolimab): Cantargia AB
  • GVAX Pancreatic Tumor Vaccine: Bristol-Myers Squibb
  • And several others

 

Request for a sample report to understand more about the Pancreatic Cancer pipeline development activities @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market

 

Pancreatic Cancer Therapeutics Assessment

Major key companies are working proactively in the Pancreatic Cancer Therapeutics market to develop novel therapies which will drive the Pancreatic Cancer treatment markets in the upcoming years are AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others.

 

Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/pancreatic-cancer-market

 

Pancreatic Cancer Report Key Insights

1. Pancreatic Cancer Patient Population

2. Pancreatic Cancer Market Size and Trends

3. Key Cross Competition in the Pancreatic Cancer Market

4. Pancreatic Cancer Market Dynamics (Key Drivers and Barriers)

5. Pancreatic Cancer Market Opportunities

6. Pancreatic Cancer Therapeutic Approaches

7. Pancreatic Cancer Pipeline Analysis

8. Pancreatic Cancer Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Pancreatic Cancer Market

 

Table of Contents

1. Key Insights

2. Executive Summary

3. Pancreatic Cancer Competitive Intelligence Analysis

4. Pancreatic Cancer Market Overview at a Glance

5. Pancreatic Cancer Disease Background and Overview

6. Pancreatic Cancer Patient Journey

7. Pancreatic Cancer Epidemiology and Patient Population

8. Pancreatic Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Pancreatic Cancer Unmet Needs

10. Key Endpoints of Pancreatic Cancer Treatment

11. Pancreatic Cancer Marketed Products

12. Pancreatic Cancer Emerging Therapies

13. Pancreatic Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Pancreatic Cancer Market Outlook (7 major markets)

16. Pancreatic Cancer Access and Reimbursement Overview

17. KOL Views on the Pancreatic Cancer Market

18. Pancreatic Cancer Market Drivers

19. Pancreatic Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting